Use of Recommended Real-World Methods for Electronic Health Record Data Analysis Has Not Improved Over 10 Years

Author:

Li ChenyuORCID,Alsheikh Abdulrahman M.ORCID,Robinson Karen A.ORCID,Lehmann Harold P.ORCID

Abstract

ABSTRACTBackground and PurposeTo document the use of recommended Real-World Methods (RWM) in Electronic Health Record (EHR)-based analysis in biomedical research over 10 years.MethodsSampled-article scoping review of methods used in EHR-based biomedical research. We developed a search strategy to identify reports of biomedical research based on EHR data and systematically sampled articles from different ranges of years (epochs) between 2010 and 2019 to establish a trajectory of use of recommended RWM. Methods were classified by 3 phases of research: pre-analytic (missing data), analytic (specific methods), and post-analytic (sensitivity analysis). The primary outcome was the proportion of studies using recommended RWM within each epoch. Meta-regressions were performed to examine trends.Data SynthesisFive epochs were defined between 2010 and 2019 with 35 studies selected per epoch as pre-defined by a sample size calculation. Of the 175 articles reviewed, 70 (40.%) reported recommended RWM in any of the 3 phases of research. The breakdown for the most recent year in the dataset, 2019, was 14.% (95% confidence interval 2.7%, 26.%), 14.% (2.7%, 26.%), and 11.% (0.89%, 22.%), for assessing missing data, using specific methods, and performing sensitivity analysis, respectively. Only 3.4 % of studies used appropriate methods for each phase of research. Meta-regression slopes for each of the three phases were statistically 0.Limitation and ConclusionsThe underuse of recommended Real-World Methods (RWM) in EHR-based biomedical research remains a concern, with less than 50% of reports using these methods in any phase of research over the last decade. This lack of use indicates a continued risk of bias in the EHR-based literature.

Publisher

Cold Spring Harbor Laboratory

Reference71 articles.

1. FDA. Real-World Evidence. Sec 2020/03/23 2020. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. 2021/12/20

2. FDA. Framework for FDA’s Real-World Evidence Program. Sec Dec. 2018 2018. https://www.fda.gov/media/120060/download.

3. Real-World Evidence — What Is It and What Can It Tell Us?

4. Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence

5. Trial designs using real‐world data: The changing landscape of the regulatory approval process

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3